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Abstract 
Objectives: We aimed to evaluate the relationship between mitral annular disjunction (MAD) severity and myocar-
dial interstitial fibrosis at the left ventricular (LV) base in patients with mitral valve prolapse (MVP), and to assess the 
association between severity of interstitial fibrosis and the occurrence of ventricular arrhythmic events.
Background: In MVP, MAD has been associated with myocardial replacement fibrosis and arrhythmia, but the impor-
tance of interstitial fibrosis remains unknown.
Methods: In this retrospective study, 30 patients with MVP and MAD (MVP–MAD) underwent cardiovascular mag-
netic resonance (CMR) with assessment of MAD length, late gadolinium enhancement (LGE), and basal segments 
myocardial extracellular volume (ECVsyn). The control group included 14 patients with mitral regurgitation (MR) but 
no MAD (MR-NoMAD) and 10 patients with normal CMR (NoMR-NoMAD). Fifteen MVP–MAD patients underwent 
24 h-Holter monitoring.
Results: LGE was observed in 47% of MVP–MAD patients and was absent in all controls. ECVsyn was higher in MVP–
MAD (30 ± 3% vs 24 ± 3% MR-NoMAD, p < 0.001 and vs 24 ± 2% NoMR-NoMAD, p < 0.001), even in MVP–MAD patients 
without LGE (29 ± 3% vs 24 ± 3%, p < 0.001 and vs 24 ± 2%, p < 0.001, respectively). MAD length correlated with 
ECVsyn (rho = 0.61, p < 0.001), but not with LGE extent. Four patients had history of out-of-hospital cardiac arrest; LGE 
and ECVsyn were equally performant to identify those high-risk patients, area under the receiver operating character-
istic (ROC) curve 0.81 vs 0.83, p = 0.84). Among patients with Holter, 87% had complex ventricular arrhythmia. ECVsyn 
was above the cut-off value in all while only 53% had LGE.
Conclusion: Increase in ECVsyn, a marker of interstitial fibrosis, occurs in MVP–MAD even in the absence of LGE, and 
was correlated with MAD length and increased risk of out-of-hospital cardiac arrest. ECV should be includedin the 
CMR examination of MVP patients in an effort to better assess fibrous remodelling as it may provide additional value 
beyond the assessment of LGE in the arrhythmic risk stratification.
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Introduction
With a prevalence of about 2% in the western popula-
tion, mitral valve prolapse (MVP) is a relatively com-
mon condition, associated with a good overall prognosis 
[1–3]. However, recent findings suggest an association 
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between MVP and ventricular arrhythmias (VA) as well 
as an increased incidence of sudden cardiac death (SCD); 
hence, the terms “arrhythmic” or “malignant” MVP 
have been coined [4–6]. The nature of this relationship 
remains only partially deciphered and identifying prog-
nostic factors and mechanisms associated with these 
events is currently emerging as a challenging task [2, 7, 
8]. Several prognostic factors have been reported in the 
literature, including negative T waves, bileaflet prolapse 
with leaflet redundancy [1, 8], polymorphic premature 
ventricular contraction (PVC) [2], flail mitral valve leaflet, 
significant mitral regurgitation (MR) [9], and most inter-
estingly left ventricular (LV) fibrosis and mitral annular 
disjunction (MAD) which seem to be key predictors of 
VA [6, 8, 10–12]. From a pathophysiological perspec-
tive, the excessive mobility of mitral valve leaflets may 
induce mechanical stretch of the inferobasal wall and of 
the papillary muscles leading to LV fibrosis. Fibrosis can 
be detected by late gadolinium enhancement (LGE) using 
cardiovascular magnetic resonance (CMR) and typically 
involves the papillary muscles and the LV basal inferior 
segment in the vicinity of the prolapsing posterior mitral 
leaflet [5, 10].
Myocardial extracellular volume (ECV) quantifica-
tion by T1 mapping has emerged as an accurate tool 
to detect ECV expansion, a quantitative marker of dif-
fuse myocardial fibrosis in ischemic and non-ischemic 
cardiomyopathies [13, 14]. Most importantly, ECV has 
been found to be an independent predictor of adverse 
outcome in patients with significant aortic stenosis [15, 
16]. In patients with MR, abnormal native T1 mapping 
indices and shorter post-contrast T1 times have been 
reported, but the clinical significance of these observa-
tions and their association with an increased risk of SCD 
or arrhythmia remain unclear [17–20].
Herein, we aimed to evaluate the relationship between 
MAD severity and myocardial interstitial fibrosis at the 
LV base quantified by T1 mapping in patients with bile-
aflet MVP. In addition, we sought to assess the associa-
tion between a history of out-of-hospital cardiac arrest 
(OHCA) and the extent of interstitial myocardial fibro-
sis, as well as the relation between myocardial fibrosis 




From the CMR registry of the Lausanne University Hos-
pital, we retrospectively included patients with a bileaf-
let MVP and MAD between January 2011 and October 
2019. MVP was defined as a systolic excursion of the 
mitral leaflets > 2  mm behind the mitral annular plane 
in the long axis view, i.e. a displacement of > 2 mm into 
the left atrium (LA) [21]. MAD was defined as the appar-
ent systolic separation of the mitral leaflet insertion from 
the ventricular myocardium [10]. As a control group, 
we included patients with various degrees of MR identi-
fied by echocardiography, who underwent CMR during 
the same period. Patients with myocardial infarction, 
myocarditis, hypertrophic cardiomyopathy, infiltrative 
heart disease, more than mild associated valvular heart 
disease and/or a LV ejection fraction (LVEF) < 50% were 
excluded. Three groups were finally constituted: (1) 
patients with MVP and MAD (MVP–MAD), (2) patients 
with MR but without MAD (MR-No MAD), and (3) 
patients with neither MR nor MAD (No MR-No MAD). 
Clinical characteristics were collected based on institu-
tional medical records. The CMR registry was approved 
by the local ethics committee CER-VD (Protocol number 
2018-00656) and the patients provided written informed 
consent for their inclusion.
Cardiovascular magnetic resonance protocol
Electrocardiogram (ECG)-gated CMR imaging was per-
formed using a 1.5T CMR system (MAGNETOM Aera 
or Sola, Siemens Healthineers, Erlangen-Germany) 
with a 32-channel phased-array surface receiver coil. 
Cine images were acquired using a breath-hold bal-
anced steady-state free precession sequence (bSSFP) 
in long-axis (2-chamber, 3-chamber and 4-chamber) 
and short-axis views (8  mm slices without gap, 10–15 
slices). Breath-hold ECG-triggered phase contrast veloc-
ity sequences for ascending aortic flow evaluation were 
acquired to estimate the aortic forward flow and cal-
culate the regurgitation fraction. For pre-contrast T1 
mapping, we used the ECG-triggered modified Look-
Locker inversion recovery (MOLLI) sequence (using 
the scheme  3(3)3(3)5) on a single short-axis basal LV 
slice. The basal slice was defined as the slice position of 
the most basal cine bSSFP slice, where a complete ring 
of myocardium was visible throughout diastole and sys-
tole. Ten minutes after the administration of a 0.2 mmol/
kg intravenous bolus of Gadobutrol (Gadovist, Bayer 
Healthcare, Berlin, Germany), LGE images were acquired 
using a 2D breath-hold phase-sensitive segmented inver-
sion-recovery gradient echo pulse sequence in the same 
orientations as cine images. Inversion-time was individu-
ally optimized to null normal myocardium. Post-contrast 
T1-mapping was acquired following LGE imaging (typi-
cally 20  min after Gadobutrol bolus injection) using a 
MOLLI sequence (4(1)3(1)2 scheme). As previously 
reported in literature [17], pre and post-contrast T1 
mapping was optimized to improve the precision of the 
measurement, in particular pre-contrast T1 mapping 
was optimized for measuring long T1s of the order of 
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1000 ms while the post contrast sequence was optimized 
for short T1s of the order of 200 ms.
Image analysis
All CMR examinations were analyzed blinded to clini-
cal characteristics and outcome using the Syngo.via soft-
ware (Siemens Healthiners) to calculate LV volumes, LV 
mass and LVEF by delineating endocardial and epicardial 
borders in the stack of short-axis cine images. The pres-
ence of myocardial LGE was visually evaluated and its 
extent was semi-quantitatively reported according to the 
American Heart Association 17 segments model [22]. In 
the MVP–MAD group, the MR volume was calculated 
according to the standard indirect method, by subtract-
ing the forward aortic flow volume from the total LV 
stroke volume (LV stroke volume − forward aortic flow). 
The MR fraction was quantified using the following equa-
tion: (regurgitant volume × 100)/(LV stroke volume). MR 
volume and regurgitant fraction corrected for the sever-
ity of the prolapse were additionally calculated as previ-
ously reported [23]. The MAD length was measured on a 
3-chamber view from the LA wall-posterior mitral leaflet 
junction to the top of the basal LV inferolateral wall dur-
ing systole (Fig. 1, Panel A).
T1 mapping
Pre- and post-contrast T1 mapping images were first vis-
ually reviewed to assess quality, and myocardial T1 relax-
ation times were then measured using the GTVolume 
software (GyroTools LLC, Zurich, Switzerland). After 
manual tracing of the endocardial and epicardial bor-
ders, the basal slice of the LV was automatically divided 
into 6 equal segments and the mean T1 relaxation time 
was calculated for each segment (Fig. 1, Panel B, C). The 
synthetic (ECVsyn) was calculated without haematocrit 
sampling as recently validated by Treibel et  al. [24] In 
particular for ECV calculation the following formula was 
used [25]:
According to the literature, synthetic haematocrit 
was previously validated against conventional haema-
tocrit. For Siemens Aera, a local calibration of the syn-
thetic haematocrit was performed on a population of 20 
healthy subjects and more than 800 patients. Following 
the change in scanner during study period, the local cali-
bration of the synthetic haematocrit was repeated for Sie-
mens Sola on a population of 256 patients. In both cases, 
a linear regression analysis was used to create a formula 
allowing synthetic haematocrit estimation from the 
measured blood relaxivity (R1) (Additional file 1: Figure 
S1). ECVsyn was then calculated using synthetic haema-
tocrit instead of measured haematocrit in the formula.
ECVsyn expansion was considered to be significant 
with an ECVsyn > 27%. The reproducibility of T1 relaxa-
tion time and ECVsyn measurement was assessed on a 
random sample of 15 patients, analyzed by two different 
operators, blinded to clinical data and both experienced 
in CMR examination analysis.
Objectives and endpoints definitions
The main objective of the study was to compare the 
severity of myocardial fibrosis (extent of LGE, pre-con-
trast T1 relaxation time and ECVsyn) at the basal LV 
myocardium and the length of MAD in MVP patients 
with and without a recent history of unexplained resus-
citated OHCA. As a secondary objective, we assessed the 
relation between the severity of myocardial fibrosis and 
the incidence of PVC and of complex PVC (grade 4 or 
5 according to Lown classification) in a subgroup of 15 
patients with suspected arrhythmic MVP, who performed 
a 24 h Holter monitoring.



















Fig. 1 A Cardiovascular magnetic resonance (CMR) 3 chambers cine 
image at end-systole for measurement of mitral annular disjunction 
(MAD) length. B, C Semi-automatic measurement of segmental 
pre-contrast (B) and post-contrast (C) T1 relaxation time of the basal 
left ventricular myocardium
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Statistical analysis
Continuous variables were expressed as mean ± SD or 
median [interquartile range] where appropriate, and 
categorical variables as numbers and percentages (n, %) 
respectively. Gaussian distribution was determined with 
the skewness and kurtosis test for normality. Differences 
in continuous variables between two groups were ana-
lysed with the independent-sample Student’s t test in 
case of normal distribution or the Mann–Whitney test in 
case of non-normal distribution. Comparisons between 
three groups were performed by ANOVA with post-hoc 
Bonferroni correction. Comparison of categorical vari-
ables was performed with the χ2 test. Correlation analy-
sis was performed using Spearman’s correlation. Receiver 
operating characteristic (ROC) analysis was used to 
determine the optimal cut-off value of selected CMR 
parameters (LGE and ECVsyn) associated with arrhyth-
mic endpoints. Considering the inhomogeneous distri-
bution of pre-contrast T1 relaxation times and ECVsyn, 
with the highest values typically located in the inferior 
and inferolateral region (i.e. at the close vicinity of the 
posterior mitral leaflet attachment), the average values 
of the basal inferior and inferolateral segments were used 
for association analyses with arrhythmic endpoints.
Reproducibility analyses for the measurement of myo-
cardial pre-contrast T1 and ECVsyn were performed 
using Pearson’s correlation and Bland–Altman statistics. 
All statistical analyses were performed using STATA 16.0 
(StataCorp, College Station, Texas, USA). A p < 0.05 was 
considered statistically significant.
Results
A total of 38 patients with MVP and MAD were identi-
fied. Five patients with complex congenital heart disease 
and 3 patients who already underwent mitral valve repair 
were excluded leaving 30 patients in the MVP–MAD 
group. Thirty-eight patients with various degrees of MR 
detected by echocardiography and without MAD where 
selected as controls. Four patients were excluded because 
of poor image quality, 6 patients because of previous 
myocardial infarction and 4 patients because of myocar-
ditis. Among the remaining 24 patients, 14 had mild to 
severe MR (MR-no MAD) and 10 had no or only a trace 
MR (no MR-no MAD).
Baseline clinical and morphological characteristics
Mean age was 50 ± 19 years and similar across the three 
groups (p = 0.82), and 43% were females. LV end-dias-
tolic volume index was higher in the MVP–MAD group 
than in the MR-No MAD and the No MR–No MAD 
groups (102 ± 29 ml/m2 vs 81 ± 17 ml/m2, p = 0.018, and 
vs 82 ± 16  ml/m2, p = 0.048 respectively), but there was 
similar LVEF (Table 1). In the MR-No MAD group, MR 
severity grade assessed by echocardiography was mild 
Table 1 Baseline clinical and cardiovascular magnetic resonance (CMR) characteristics
ECVsyn synthetic extracellular volume fraction, LV left ventricle, LVEDV left ventricle end-diastolic volume, LVEDVI left ventricle end-diastolic volume index, LVEF left 
ventricle ejection fraction, LGE late gadolinium enhancement Gd gadolinium, MAD mitral annular disjunction, MVP mitral valve prolapse
MVP–MAD
n = 30
Control group (No MVP)
MR-NoMAD
n = 14
P vs MVP–MAD NoMR-NoMAD
n = 10
P vs MVP–MAD
Age (y) 50 ± 17 53 ± 22 0.70 46 ± 21 0.53
Male, n (%) 18 (60%) 7 (50%) 0.75 6 (60%) 1.0
Weight (kg) 72 ± 12 70 ± 14 0.69 82 ± 13 0.02
Height (cm) 177 ± 10 170 ± 10 0.04 179 ± 11 0.65
Hypertension, n (%) 2 (7%) 6 (43%) 0.008 2 (20%) 0.26
Active smoker, n (%) 3 (10%) 1 (7%) 1.0 1 (10%) 1.0
Hyperlipidaemia, n (%) 2 (7%) 2 (14%) 0.58 2 (20%) 0.26
LVEDV (ml) 192 ± 56 148 ± 39 0.01 164 ± 29 0.14
LVEDVI (ml/m2) 102 ± 29 81 ± 17 0.018 82 ± 16 0.048
LVESV (ml) 84 ± 32 60 ± 21 0.02 70 ± 12 0.20
LVEF (%) 57 ± 8 60 ± 8 0.32 57 ± 3 0.99
LV mass index (g/m2) 66 ± 16 62 ± 15 0.45 63 ± 9 0.59
MAD length (mm) 9.4 [7.1–12.3] – –
Presence of LGE, n (%) 14 (47%) 0 (0%) 0.002 0 (0%) 0.007
 N of positive segments (n = 14) 3 [3–4] 0 0
Basal slice pre-Gd T1 (ms) 1067 ± 45 1029 ± 37 0.009 1029 ± 26 0.016
Basal slice ECVsyn (%) 30 ± 3 24 ± 3 < 0.0001 24 ± 2 < 0.0001
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in 7 patients (50%), moderate in 5 (36%) and severe in 2 
(14%).
In MVP–MAD the maximum MAD length was 9.4 mm 
[7.1–12.3]. Phase contrast aortic flow data were avail-
able in only 22 MVP–MAD patients and the mean mitral 
regurgitant fraction was 31 ± 17%. After correction 
for the prolapsing volume, the mean MR fraction was 
16 ± 21%. MR severity grade assessed by echocardiog-
raphy was available in 27 MVP–MAD patients and MR 
was graded as mild in 9 (50%), moderate in 14 (36%) and 
severe in 4 (14%) patients.
Tissue characterization
LGE was present in 14 MVP–MAD patients (47%) and 
was absent in the two other groups. In LGE-positive 
patients, the median LGE extent was 3 [3–4] segments, 
and LGE was most frequently detected in the basal to 
mid-ventricular inferior and inferolateral walls (i.e. 
in the vicinity of the posterior mitral leaflet attach-
ments) compared with the anterior and antero-lateral 
walls (47% vs 10%, p = 0.002) and the antero-septal and 
infero-septal walls (47% vs 13%, p = 0.005) (Fig. 2).
Native T1 relaxation was higher in MVP–MAD 
in comparison with MR-No MAD (1067 ± 45  ms 
vs 1029 ± 37  ms, p = 0.009) and No MR-No MAD 
(1029 ± 26 ms, p = 0.016) (Fig. 3). LGE negative MVP–
MAD patients had a native T1 similar to LGE positive 
MVP–MAD patients (1057 ± 49  ms vs 1078 ± 39  ms, 
p = 0.19), and significantly higher than controls 
(1057 ± 49 ms vs 1029 ± 32 ms, p = 0.04).
The ECVsyn was higher in MVP–MAD compared 
with MR-No MAD (30 ± 3% vs 24 ± 3%, p < 0.001) 
and No MR-No MAD (30 ± 3% vs 24 ± 2%, p < 0.001) 
(Fig.  4). In the MVP–MAD group, LGE negative 
patients had ECVsyn values similar to LGE positive 
patients (29 ± 3% vs 31 ± 3%, p = 0.19), and significantly 
higher than controls (29 ± 3% vs 24 ± 2%, p < 0.001). 
Interestingly, 87% of the MVP–MAD patients had an 
Fig. 2 Distribution of late gadolinium enhancement (LGE) positivity 
in patients with mitral valve prolapse (MVP) and MAD (n = 30). A 
anterior, AL anterolateral, IL inferolateral, I inferior, IS inferoseptal, AS 
anteroseptal
Fig. 3 Pre-contrast T1 relaxation time measured in the six basal myocardial segments. The average T1 relaxation time is indicated in the center of 
each plot. Abbreviations: see Fig. 2
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ECVsyn above the upper normal limit (> 27%). This 
proportion was 93% in LGE-positive vs 81% in LGE-
negative patients (p = 0.35), and no significant cor-
relation was found between LGE extent and ECVsyn 
(rho = 0.10, p = 0.60).
No significant correlation was found between MAD 
length and LGE extent (rho = − 0.01, p = 0.97) or 
between MAD length and pre-contrast native  T1 
(rho = 0.26, p = 0.16) but a moderate to high correlation 
was found between MAD length and ECVsyn (r = 0.61, 
p < 0.001) (Fig. 5).
Among the 27 MVP–MAD patients with echocar-
diographic quantification of MR severity, no significant 
difference was observed among the three MR severity 
grades for MAD length (8.4 [7.1–10.2] with mild MR vs 
10.9 [9–14.6] with moderate MR vs 8.1 [4.2–12.4] mm 
with severe MR, respectively, p = 0.16), LGE extent (0 
[0–2] vs 0 [0–4] vs 3 [1.5–3.5] segments, p = 0.58), T1 
relaxation time (1075 ± 45 vs 1059 ± 44 vs 1042 ± 37 ms, 
Fig. 4 Extracellular volume (ECV) calculated in the six basal myocardial segments. The average ECV is indicated in the center of each plot. 
Abbreviations: see Fig. 2
Fig. 5 Relation between MAD distance and parameters of myocardial fibrosis
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p = 0.50) and ECVsyn (31 ± 5 vs 30 ± 2 vs 28 ± 2%, 
p = 0.31).
Associations between, MAD length, myocardial fibrosis, 
and OHCA
Among the 30 MVP–MAD patients, 4 (13%) were 
referred for evaluation following OHCA. None of the 
patients had evidence of coronary heart disease on cor-
onary angiogram. The clinical characteristics of the 4 
patients with history of OHCA are presented in Table 2. 
Although there was no difference in MAD length (11.2 
[8.7–13.0] vs 9.1 [6.5–12.3] mm, p = 0.50), significant dif-
ferences were found in terms of body weight (85 ± 9 kg in 
OHCA patients vs 70 ± 11 kg, p = 0.01) and presence of 
LGE (100% in OHCA patients vs 38%, p = 0.04). OHCA 
patients had a higher LGE extent (3.5 [2.5–5.5] vs 0 [0–3] 
segments positive for LGE, p = 0.02). No difference was 
found in terms of pre-contrast T1 values (1133 ± 72 
vs 1085 ± 57  ms, p = 0.14) but a significantly higher 
ECVsyn was measured in OHCA patients (35.1 ± 4.4% 
vs 30.7 ± 3.6%, p = 0.03) (Fig. 6). Regarding the identifica-
tion of patients with history of OHCA, the presence of 
LGE achieved a sensitivity of 100%, a specificity of 62%, 
a positive predictive value of 29%, and a negative predic-
tive value of 100%. For an ECVsyn threshold > 33.5%, they 
were 75%, 85%, 43%, and 96%, respectively. The ROC 
analysis revealed comparable accuracy of ECVsyn and 
LGE for the detection of patients with previous OHCA 
(area under the ROC curve 0.832 vs 0.808, p = 0.84).
Of note, MR was mild in 3 and moderate in one OHCA 
patient. The mean MR severity grade in OHCA tended 
to be lower than in patients with no previous OHCA 
(1.25 ± 0.5 1.91 ± 0.67, p = 0.07), but the difference was 
not significant.
Association between myocardial fibrosis and arrhythmia
The baseline characteristics of the 15 patients investi-
gated with a Holter monitoring are presented in Table 3. 
The median time between Holter monitoring and CMR 
was 36 days [1–113 days]. The only significant difference 
between patients with rhythm assessment compared to 
patients without was a higher ECVsyn of the basal infero-
posterior region (33 ± 5 vs 30 ± 3%, p = 0.03). All patients 
Table 2 Characteristics of the MVP–MAD patients with and 
without history of OHCA
Statistically significant correlations are given in bold
ECVsyn synthetic extracellular volume, LV left ventricle, LVEDV left ventricle 
end-diastolic volume, LVEDVI left ventricle end-diastolic volume index, LVEF 
left ventricle ejection fraction, LVESV, left ventricular end-systolic volume. LGE 
late gadolinium enhancement, Gd gadolinium, MAD mitral annular disjunction, 
OHCA out-of-hospital cardiac arrest
a Mean value of inferior and inferolateral segments
OHCA (n = 4) No OHCA (n = 26) p
Age (y) 58 ± 7 49 ± 18 0.33
Male, n (%) 1 (25%) 17 (65%) 0.27
Weight (kg) 85 ± 9 70 ± 11 0.01
Height (cm) 178 ± 16 177 ± 10 0.87
LVEDV (ml) 154 ± 16 198 ± 58 0.15
LVEDVI (ml/m2) 77 ± 15 106 ± 29 0.06
LVESV (ml) 62 ± 27 87 ± 32 0.15
LVEF (%) 60 ± 14 56 ± 8 0.40
LV mass index (g/m2) 60 ± 6 67 ± 17 0.43
MAD length (mm) 11.2 [8.7–13.0] 9.1 [6.5–12.3] 0.50
Presence of LGE, n (%) 4 (100%) 10 (38%) 0.04
 N of positive segments 3.5 [2.5–5.5] 0 [0–3] 0.02
Basal slice pre-Gd T1 (ms)a 1133 ± 72 1085 ± 57 0.14
Basal slice ECVsyn (%)a 35 ± 4 31 ± 4 0.03
Fig. 6 Comparison of fibrosis parameters in patients with and without out-of-hospital cardiac arrest
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with Holter experienced PVC with a median incidence of 
2.8% [1.1–10.3%] of all heartbeats. Complex PVC were 
detected in 13 patients (87%) and NSVT (non-sustained 
ventricular tachycardia) in 10 (67%) with a median of 5 
[0–17] runs/24  h. LGE was detected in only 8/15 (53%) 
patients while all patients had an ECVsyn > 27% in the 
basal infero-posterior region. ECVsyn was not sig-
nificantly different between patients with and with-
out LGE detected (34.5 ± 5 vs 32 ± 4%, p = 0.47). There 
was no significant difference in PVC count between 
patients with and without LGE (4.2% [1.6–8.7%] vs 2.8% 
[0–14.9%], p = 0.82). Similarly, PVC count was not sig-
nificantly higher in patients with a higher pre-contrast 
T1 (T1 ≥ 1115 ms corresponding to the median T1 value 
of the basal infero-posterior region: 7.1% [1.3–14.9%] vs 
2.2% [0.8–7.1%], p = 0.22), and in patients with a higher 
ECVsyn (ECVsyn ≥ 32.0% corresponding to the median 
ECVsyn value of the basal infero-posterior region: 2.8% 
[1.1–10.3%] vs 4.2% [1.2–11.7%], p = 0.77).
Intra- and inter-observer reproducibility of T1- and ECVsyn 
measurements
Intra-observer (r = 0.61, p = 0.004/Mean difference 
9  ms − 95% levels of agreement—70 to 89  ms) and 
inter-observer (r = 0.93, p < 0.001/Mean difference 
11  ms − 95% levels of agreement—25 to 46  ms) repro-
ducibility for pre-contrast T1 relaxation time was good. 
Both intra-observer (r = 0.99, p < 0.001/Mean difference 
0–95% levels of agreement −  0.3% to 0.4% ms) and 
inter-observer (r = 0.99, p < 0.001/Mean difference 0% 
ms − 95% levels of agreement − 0.4% to 0.4%) reproduc-
ibility were excellent for ECVsyn calculation (Figs. 7 and 
8).
Discussion
In this retrospective study we found that (1) MVP–MAD 
patients had a higher ECVsyn indicative of a higher 
amount of interstitial fibrosis even in the absence of 
detectable LGE, (2) MAD length was best associated with 
a higher ECVsyn but not with a higher native T1 or LGE 
extent, and (3) the presence of LGE and a basal posterior 
ECVsyn > 33.5% identified MVP–MAD patients with his-
tory of OHCA with similar accuracy.
MVP is a relatively frequent clinical condition with 
a good overall prognosis. However, VA and SCD may 
occur with an incidence of 0.2% to 0.4% per year in 
this population [1, 3, 9, 26]. Therefore, the identifica-
tion of risk factors of VA is of paramount importance. 
Myocardial fibrosis detected by LGE has been associ-
ated with the occurrence of VA in several ischemic and 
non-ischemic cardiac conditions using CMR [27–30]. 
However, the precise detection of fibrosis may be chal-
lenging in areas where the myocardium is not completely 
replaced by fibrotic tissue [31] as these inhomogeneous 
areas are characterized by an intermediate intensity (grey 
zone) due to the intermingling of both viable myocar-
dium and interstitial fibrosis. They are typically present 
in the border zone of ischemic scars, or associated with 
non-ischemic cardiomyopathies or inflammatory heart 
diseases and may promote re-entry pathways for VA [32–
34]. The newer T1 mapping technique provides comple-
mentary information on fibrotic remodelling as it allows 
a quantitative assessment of myocardial ECV, a marker 
of extracellular matrix expansion [14, 35, 36]. Although 
increased ECV identifies patients at higher risk of mor-
tality or heart failure [37], its value in predicting adverse 
arrhythmic outcomes remains unknown.
In patients with MVP and MAD, increasing evi-
dence supports an association between prolapse sever-
ity, curling motion of the basal posterior myocardium 
and structural changes of the myocardium. The con-
tinuous mechanical stretch applied by the MVP has 
been suggested to induce a fibrotic remodelling of the 
basal inferior LV wall and the papillary muscles [10, 38], 
where LGE could be detected in 73% and 83% of cases, 
respectively [10]. MAD itself appears to play an impor-
tant role in the pathogenesis of VA. In a large cohort of 
116 patients with MAD, in which 12% of the popula-
tion presented with severe arrhythmic events, Dejgaard 
et al. observed that MAD was a distinct entity linked to 
arrhythmia severity, whereas isolated MVP was not [11]. 
Table 3 Characteristics of patients with and without Holter 
monitoring
Statistically significant correlation is given in bold
ECVsyn synthetic extracellular volume, LV left ventricle, LVEDV left ventricle 
end-diastolic volume, LVEDVI left ventricle end-diastolic volume index, LVEF left 
ventricle ejection fraction; LGE late gadolinium enhancement, Gd gadolinium, 
MAD mitral annular disjunction
a Mean value of inferior and inferolateral segments
Holter (n = 15) No Holter (n = 15) p
Age (y) 47 ± 14 53 ± 19 0.34
Male, n (%) 8 (53%) 10 (67%) 0.71
Weight (kg) 74 ± 11 70 ± 13 0.41
Height (cm) 176 ± 7 178 ± 13 0.45
LVEDV (ml) 191 ± 45 193 ± 67 0.93
LVEDVI (ml/m2) 102 ± 25 103 ± 34 0.92
LVESV (ml) 85 ± 23 83 ± 39 0.92
LVEF (%) 55 ± 8 58 ± 9 0.33
LV mass index (g/m2) 65 ± 10 66 ± 20 0.83
MAD length (mm) 9.6 [7.6–14.6] 9.1 [6.3–11.4] 0.30
Presence of LGE, n (%) 8 (53%) 6 (40%) 0.72
 N of positive segments 3 [2.5–4] 3.5 [3–4] 0.59
Basal slice pre-Gd T1 (ms)a 1109 ± 49 1073 ± 66 0.11
Basal slice ECVsyn (%)a 33 ± 5 30 ± 3 0.03
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Several clinical and pathological studies have revealed 
an association between bileaflet MVP with MAD, focal 
fibrosis within the infero-lateral LV segment or papillary 
muscles, and an increased risk of arrhythmia [6, 7, 10, 21, 
26]. Interestingly, in our cohort only 47% of MVP–MAD 
patients had LGE detected in the LV but 87% had a mean 
ECV above the upper limit of 27% in the basal LV myo-
cardium. An ECVsyn > 27% was not only found in 93% of 
LGE-positive, but also in 81% of LGE-negative MVP-MD 
patients. Moreover, an ECVsyn was increased in all the 
basal segments, suggesting that fibrotic remodelling is 
not restricted to the basal inferior/infero-lateral region, 
but develops in all myocardium adjacent to the insertion 
of the prolapsing valve. Our findings indicate that detec-
tion of confluent fibrosis using LGE alone may underesti-
mate the fibrotic remodelling of the basal myocardium in 
relation to severe MVP and MAD.
The association between MVP and interstitial fibrosis, 
and its relation to VA has seldom been investigated. In a 
series published by Pradella et al. patients with MVP had 
Fig. 7 Intra-observer reproducibility of pre-contrast T1 relaxation time (left hand panels) and extracellular volume (right hand panels) 
measurements
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higher native and lower post-contrast T1 myocardial val-
ues, but no association with complex VA was found [17]. 
Bui et al. also detected an association between MVP and 
reduced post-contrast T1 times, suggesting increased 
myocardial fibrosis. Interestingly, in their series, MVP 
patients with complex VA had lower post-contrast T1 
times compared to MVP patients with no arrhythmia 
making the authors conclude that interstitial remodel-
ling may contribute to ventricular arrhythmogenesis [18]. 
However both studies did not evaluate the presence of 
MAD nor calculated the ECV. In the present study, the 
magnitude of the MAD was strongly correlated to the 
extent of interstitial fibrosis assessed by ECV, but was not 
associated with macroscopic fibrosis evaluated by LGE. 
This suggests that ECV may provide a more comprehen-
sive assessment of LV remodelling induced by MVP–
MAD. Based on studies focusing on ischemic heart 
disease [32–34, 39], we hypothesized that the presence 
Fig. 8 Inter-observer reproducibility of pre-contrast T1 relaxation time (left hand panels) and extracellular volume (right hand panels) 
measurements
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of interstitial fibrosis (i.e. high ECVsyn) could be predic-
tive of VA in MVP–MAD patients. Rhythm assessment 
was obtained in 15 higher risk patients referred for sus-
pected MVP arrhythmic syndrome and complex VA 
(either complex PVC or NSVT) were detected in almost 
all of them. Surprisingly, LGE was detected in only half 
of the patients but an increase in ECVsyn above the cut-
off value was measured in all. Furthermore, ECVsyn was 
comparably increased in patients with and without LGE, 
supporting the hypothesis of an implication of interstitial 
fibrosis, and not only replacement fibrosis, in the devel-
opment of VA in MVP–MAD patients. Several patterns 
of remodeling may be linked to the arrhythmic risk in 
MVP: either focal replacement fibrosis assessed by LGE 
or interstitial fibrosis measured with T1 mapping. This 
is in line with the description that VA in MVP can arise 
from the fascicular region or the septal regions of the 
mitral annulus in electrophysiological studies, and not 
only from regions presenting focal macroscopic fibrosis 
[4]. Finally and most importantly, we found a similar pre-
dictive value for OHCA between ECVsyn and LGE extent 
in our series, which supports systematically perform-
ing ECVsyn measurements in addition to LGE assess-
ment during CMR examinations of patients with MVP. 
This parameter may provide additional prognostic value 
beyond LGE, as its fair specificity may complement the 
assessment of LGE in the unmet challenge of primary 
prevention risk stratification.
Given the retrospective nature of the study, synthetic 
haematocrit was used to calculate the ECV, as previ-
ously described in literature [24, 40, 41]. Until now, some 
concerns have been raised regarding the reliability of 
synthetic haematocrit estimations, for instance in the 
presence of haematologic disorders [42] or in the paediat-
ric population [43], where significant variations between 
measured and ECVsyn have been observed. Furthermore, 
the importance of a local calibration of the synthetic 
haematocrit, which can vary among different scanners, 
has been highlighted. In our center ECVsyn calcula-
tion has been calibrated from a large cohort of patients, 
no haematologic disorders were present and all patients 
were > 18 years old. Therefore, the potential inaccuracies 
associated with this simplified method have been mini-
mized and we believe that the ECVsyn used in this study 
reflects the true myocardial ECV of the population.
Limitations
The present study has several limitations. First, it is an 
observational, retrospective study, including a limited 
number of patients. Although our population was com-
parable in terms of arrhythmic MVP. Complex arrhyth-
mia were detected in almost all of them, an evidence of 
a likely selection bias toward higher arrhythmic risk. 
Fourth, although we used high resolution bright-blood 
LGE-CMR and images were interpreted by expert opera-
tors, routine evaluation of the presence of fibrosis in the 
papillary muscles area could prove challenging in routine 
and was not part of our analysis. Fifth, MR severity was 
not systematically evaluated during CMR examinations 
and we cannot assess the influence of MR severity on risk 
prediction. Sixth, no histologic confirmation of intersti-
tial or replacement fibrosis could be obtained and all our 
results are based on indirect CMR markers of myocardial 
fibrosis. Finally, patients underwent to CMR examination 
in two different scanners (Siemens Aera and Siemens 
Sola); however local calibration of synthetic haemato-
crit was performed for both scanners, aim at to obtain-
ing a reliable estimation of the synthetic haematocrit and 
ECVsyn.
Conclusion
In patients with MVP–MAD, remodelling of the LV 
occurs and both focal replacement and interstitial myo-
cardial fibrosis can be detected by CMR. Compared 
to LGE extent, ECVsyn of the basal LV segments had a 
stronger association with MAD severity, and a similar 
association with OHCA. Our data suggest that ECVsyn 
should be part of the CMR examination of MVP patients 
in an effort to better assess fibrous remodelling as it may 
provide additional value beyond the assessment of LGE 
in the arrhythmic risk stratification.
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